Investigating immune regulators in healthy and AML patient-derived PBMCs revealed that all cellular subsets apart from CD8+ and DN T cells responded by one or more markers after IFNα-2b treatment in healthy donor PBMCs. This evidence concerns the gene IFNA2 and acute myeloid leukemia.